Company:Vaccitech

From HandWiki
Revision as of 17:23, 27 July 2022 by imported>Len Stevenson (change)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Biotechnology company in Oxford, England
Vaccitech plc
TypePublic
NASDAQVACC
IndustryVaccines
Immunotherapy
Biotechnology
Founded2016 (2016)
Founder
  • Sarah Gilbert
  • Adrian V. S. Hill
Headquarters
Oxford Science Park, Oxford
,
Websitevaccitech.co.uk

Vaccitech plc is a biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, such as hepatitis B, HPV and prostate cancer.[1][2]

Technology

The company's platform includes Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two viral vectors which safely mimic viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours.[3]

History

The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at The Jenner Institute, University of Oxford.[4][5][6]

Vaccitech has been financed and supported by Google Ventures (GV), Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[7]

In early 2020, Vaccitech and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform.

COVID-19 vaccine

In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.[8]

In July 2020, Vaccitech scientists reported in The Lancet a "single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein." Several subjects needed prophylactic paracetamol to minimize their adverse reactions.

References